Toxic epidermal necrolysis in a 37-year-old man with pneumonia: a case report

Authors

  • Wiryanti Ambarita Firdaus Hospital, North Jakarta, Indonesia
  • Sri Lestari Department of Dermatology, Firdaus Hospital, North Jakarta, Indonesia
  • Anwar Fuadi Puri Cinere Hospital, Depok, Indonesia
  • Ali Raza Glaxo Smith Kline (GSK), Worldwide

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20240398

Keywords:

TEN, Pneumonia, SCORTEN

Abstract

Apart from allergy, TEN can be caused by infection, such as M. pneumoniae infection. Aim of this case report is to present clinical manifestations of TEN with pneumonia. A 37-year-old man, came to the emergency room with cough and fever since 5 days before hospitalized. The patient received intravenous ceftriaxone (with negative skin test), paracetamol, and n-acetylcysteine. Three days earlier, the patient had gone to primary health center and got paracetamol and n-acetylcysteine. On the first day of treatment, erythematous macules were seen on the anterior and posterior thoracic region, also the patient had sore throat and dysphagia, treated with intravenous dipenhydramine, mefenamic acid, and cetirizine. On the following day, the lesions expanded with multiple bullae on the anterior and posterior thoracic region, and erosion on the labia (BSA 28%). Intravenous methylprednisolone was administered, also Kloderma® and Ikagen® cream, and Kenalog®. Mefenamic acid and paracetamol were discontinued. On the third day of treatment, the lesions expanded (BSA 38%) and the next day, BSA reached 91.5%. The SCORTEN was 1. The patient was referred for treatment at the burn center and IVIg therapy. After the eleventh day of treatment at the referral hospital, the patient was fully recovered. The managements of TEN are stop suspected drugs, wound care, fluid therapy, systemic corticosteroids, and IVIg therapy. Appropriate management of TEN gives complete recovery to patient.

Metrics

Metrics Loading ...

References

Allanoure LJJ. Epidermal necrolysis In: Fritzpatrick’s Dermatology General Medicine. 8 ed. Goldsmith LA KS, Gilcherst BA, , Paller AS LD, Wolf K, editors. New York: Mc Graw Hill. 2013.

Watanabe TGH, Saigusa Y, Takamura N, Naoko T, Yuko W, Yumiko Y et al. Mortality and risk factors on admission in toxic epidermal necrolysis: A cohort study of 59 patients. Allergol Int. 2021;70(2):229-34.

Frey NJJ, Bodmer M, Michael B, Andreas B, Susan SJ, Christoph RM et al. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the UK. J Invest Dermatol. 2017;137(6):1240-7.

Wang Y, Chen CB, Tassaneeyakul W, Yoshiro S, Michiko A, Siew EC et al. The Medication Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label. Clin Pharmacol Ther. 2019;105(1):112-20.

Lim WS. Pneumonia-Overview. Encyclopedia Respiratory Med. 2022:185-97.

Guz DBM, Steinberg Y, Kozlovsky D, Gafter-Gvili A, Avni T. Ceftriaxone versus ampicillin for the treatment of community-acquired pneumonia: A propensity matched cohort study. Clin Microbiol Infect. 2023;29(1):70-6.

Rajan AK. Ceftriaxone induced Steven Johnson syndrome: A case report. Int J Pharmaceutical Sci Rev Res. 2020;65:124-7.

Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L, Neil HS. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am J Clin Dermatol. 2015;16(6):475-93.

Fitriana A EA, Hidayati AN. Gambaran Klinis Steven Johnson Syndrome dan Toxic Epidermal Necrolysis pada Pasien Anak. Berkala Ilmu Kesehatan Kulit dan Kelamin Periodical Dermatol Venereol. 2018;30(2):102-10.

Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010;5(39):1-11.

Finkelstein YGS, Acuna P, George M, Pope E, Ito S. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;128(4):723-28.

Sharma VKSG, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: A retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol. 2008;78:238-40.

Morita K, Matsui, H., Michihata N, Kiyohide F, Hideo Y. Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database. Am J Clin Dermatol. 2019;29:579-92.

Stella M, Cassano P, Bollero D, Clemente A, Giorio G. Toxic Epidermal Necrolysis Treated with Intravenous High-Dose Immunoglobulins: Our Experience. Dermatology. 2001;203(1):45-9.

Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunolo. 2006;97(3):272-81.

Downloads

Published

2024-02-23

How to Cite

Ambarita, W., Lestari, S., Fuadi, A., & Raza, A. (2024). Toxic epidermal necrolysis in a 37-year-old man with pneumonia: a case report. International Journal of Research in Dermatology, 10(2), 106–109. https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20240398

Issue

Section

Case Reports